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Abstract
The anti-apoptotic protein Mcl-1 plays a major role in multiple myeloma (MM) cell survival as well as bortezomib- and
microenvironmental forms of drug resistance in this disease. Consequently, there is a critical need for strategies capable of
targeting Mcl-1-dependent drug resistance in MM. The present results indicate that a regimen combining Chk1 with MEK1/2
inhibitors effectively kills cells displaying multiple forms of drug resistance stemming from Mcl-1 up-regulation in
association with direct transcriptional Mcl-1 down-regulation and indirect disabling of Mcl-1 anti-apoptotic function
through Bim up-regulation and increased Bim/Mcl-1 binding. These actions release Bak from Mcl-1, accompanied by Bak/
Bax activation. Analogous events were observed in both drug-naı¨ve and acquired bortezomib-resistant MM cells displaying
increased Mcl-1 but diminished Bim expression, or cells ectopically expressing Mcl-1. Moreover, concomitant Chk1 and
MEK1/2 inhibition blocked Mcl-1 up-regulation induced by IL-6/IGF-1 or co-culture with stromal cells, effectively overcoming
microenvironment-related drug resistance. Finally, this regimen down-regulated Mcl-1 and robustly killed primary CD138+
MM cells, but not normal hematopoietic cells. Together, these findings provide novel evidence that this targeted
combination strategy could be effective in the setting of multiple forms of Mcl-1-related drug resistance in MM.
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Introduction
Multiple myeloma (MM) is a clonal accumulative disease of
mature plasma cells which, despite recent treatment advances, is
generally fatal [1,2]. As in numerous other malignancies, MM is
characterized by dysregulation of apoptotic regulatory proteins of
the Bcl-2 family [3,4]. Among these, the anti-apoptotic protein
Mcl-1, encoded by the Mcl-1 (myeloid leukemia cell-1) gene
located on chromosome 1q21, has been implicated in the
pathogenesis of various malignancies, particularly MM [5,6].
Mcl-1 promotes proliferation, tumorigenesis, and drug resistance
of MM cells [3,5]. Notably, whereas Mcl-1 represents a factor
critical for MM cell survival [4], it has also been shown to confer
resistance to the proteasome inhibitor bortezomib, one of the most
active agents in current MM therapy [7–9]. Of note, Mcl-1 is
over-expressed in cells from MM patients, and correlates with
relapse and short survival [10]. Moreover, it is widely recognized
that the bone marrow microenvironment (BMME) plays an
important role in MM cell survival [2,11,12]. Furthermore, tumor-
microenvironment interactions confer drug resistance to diverse
drug classes [13,14] and may limit the translational potential of
promising pre-clinical approaches [11,15]. Consequently, thera-
peutic strategies targeting tumor-microenvironment interactions
represent an area of intense interest in MM [12,16]. Significantly,
several studies suggest that Mcl-1 also plays an important role in
microenvironment-related form of drug resistance in MM
[9,17,18].
Mcl-1 pro-survival activities have been primarily attributed to
interactions with pro-apoptotic Bcl-2 family members such as Bak
and Bim [19,20], although this protein binds to multiple Bcl-2
family members. Mcl-1 expression is regulated at the transcrip-
tional, translational, and post-translational levels [21], and is
distinguished by a short half-life (e.g., 30 min to 3 h.) [5,6]. This
has prompted efforts to down-regulate Mcl-1 expression in MM
and other Mcl-1-related malignancies e.g., utilizing CDK inhib-
itors/transcriptional repressors [20,22] or translational inhibitors
(e.g., sorafenib) [23], among others. An alternative strategy
involves the use of BH3 mimetics which bind to and inactivate
multi-domain anti-apoptotic proteins. While some of these (e.g.
ABT-737 or ABT-199) display low avidity for and minimal activity
against Mcl-1 [24,25], others, including pan-BH3 mimetics such
as obatoclax, act against this protein [19,26]. However, the latter
agent is no longer being developed clinically. Moreover, questions
have arisen regarding the specificity of putative Mcl-1 antagonists
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[27]. Collectively, these considerations justify the search for
alternative strategies capable of circumventing Mcl-1-related drug
resistance.
Chk1 is a protein intimately involved in the DNA damage
response [28,29]. Exposure of MM cells to Chk1 inhibitors
induces MEK1/2/ERK1/2 activation through a Ras- and Src-
dependent mechanism. Moreover, interrupting this event by
clinically relevant agents targeting the Src/Ras/MEK/ERK
pathway synergistically induces MM cell apoptosis in vitro and in
vivo [28,30,31]. Evidence that interruption of the MEK1/2/
ERK1/2 pathway down-regulates Mcl-1 expression [32] and/or
alters its associations with pro-apoptotic effectors (e.g., Bak and
Bim) [33–35] raised the possibility the Chk1/MEK1/2 inhibitor
strategy might be active in the face of Mcl-1-related forms of drug
resistance in MM. However, no information is currently available
concerning whether this strategy would be effective in this setting,
and if so, by what mechanism(s). Here we report that Chk1/
MEK1/2 inhibition induces pronounced apoptosis in bortezomib-
resistant MM cells exhibiting Mcl-1 up-regulation, and overcomes
drug resistance stemmed from IL-6, IGF-1, or stromal cells. The
present findings also suggest two distinct but interrelated
mechanisms by which this strategy may target Mcl-1, including
transcriptional down-regulation of Mcl-1 and inhibition of its anti-
apoptotic function. Collectively, these findings highlight an
alternative approach to circumventing Mcl-1-dependent bortezo-
mib- and microenvironment-related drug resistance in MM.
Materials and Methods
Cells and reagents
Human MM cell lines U266 and NCI-H929, and human bone
marrow stromal cell (BMSC) line HS-5 were purchased from
ATCC and maintained as described previously [36]. RPMI8226
cells were from Dr. Alan Lichtenstein (University of California,
Los Angeles) [37]. Dexamethasone-sensitive (MM.1S) and -
resistant (MM.1R) cell lines were provided by Dr. Steven T.
Rosen (Northwestern University, Chicago, IL) [38]. U266/Mcl-1
and RPMI8226/Mcl-1 cells were established by stably transfecting
with a construct encoding human full-length Mcl-1 as before [20].
Bortezomib-resistant U266 cells (PS-R) [20] and OPM2 cells
(V10R) [39] were generated and maintained as described
previously, all experiments were performed using logarithmically
growing cells (3–66105cells/ml).
BM samples were obtained with written informed consent
according to the Declaration of Helsinki from nine MM patients
undergoing routine diagnostic aspiration with VCU IRB approval.
CD138+ and CD1382 cells were separated using the MACS
magnetic separating system according to the manufacturer’s
instructions (Miltenyi Biotech, Auburn, CA) [30]. Briefly, mono-
nuclear cells were isolated from bone marrow samples by Ficoll-
Hypaque (Sigma, St Louis, MO), and then incubated with MACS
CD138 microbeads at 4uC for 15 minutes. CD138+ cells were
then isolated using an MS+/LS+ column and a magnetic
separator. The purity of CD138+ cells (.90%) was determined
by CD138-PE staining and flow cytometry. Viability (.95%) of
both CD138+ and CD1382 cells was assessed by trypan blue
exclusion. Isolated cells were maintained in RPMI 1640 medium
containing 10% FCS in 96-well plates. Normal BM CD34+ cells
were purchased from Lonza (Walkersville, MD). Purity of CD34+
cells was .95% and viability .80% when thawed.
The pre-clinical Chk1 inhibitor CEP3891 [29,36] was provided
by Cephalon. The MEK1/2 inhibitor PD184352 (formerly
Upstate Biotech, now Millipore) [40], analogous to the first
MEK1/2 inhibitor (PD325901) to be used in humans. Dexameth-
asone and melphalan were purchased from Sigma (St. Louis, MO).
Reagents were dissolved in sterile DMSO (final concentration
,0.1%). Melphalan was dissolved in HCl-ethanol. Recombinant
human IL-6 and IGF-I were purchased from Sigma (St. Louis,
MO) and R&D Systems (Minneapolis, MN) respectively, rehy-
drated in PBS and 10 mM acetic acid (containing 0.1% BSA). All
reagents were stored at 280uC.
Analysis of effects of the microenvironment on MM cell
viability
To assess effects of stromal cells on drug activity, a co-culture
model of MM cells with human BMSCs (HS-5) was employed
[11,41,42]. Briefly, MM cells were stably transfected with a
construct expressing luciferase (Luc) or GFP (phrGFP Vector,
Agilent Technologies) [20]. HS-5 cells were pre-plated for 48 h on
multi-well plates or Lab-Tek Chamber Slide System (Nalge Nunc,
Naperville, IL), followed by seeding Luc- or GFP-expressing MM
cells and co-culturing for an additional 24 h. After drug treatment
(48 h), cells were subjected to the following analyses: a) biolumi-
nescent assay using luciferin (RPI, Mount Prospect, IL) by
Envision Multilabel Reader (PerkinElmer, Waltham, MA); b) flow
cytometry after staining with 7AAD; c) microphotography using
an Olympus IX71 Inverted Fluorescence Microscope with CS-
DIM imaging software (Olympus, Centervalley, PA) after 7AAD
(0.5 mg/ml) staining at 37uC for 20 min; d) assessment of colony-
forming ability after 3 weeks by fluorescence microscopy as above
(colonies were defined as clusters of.50 GFP+ cells); or e) Western
blot analysis. In parallel, HS-5-conditional medium was prepared
and used as described previously [20].
Western blot analysis
Whole-cell lysates were extracted using Triton X-100 lysis
buffer containing 1% Triton X-100, 50 mM HEPES (pH 7.5),
5 mM EDTA, 50 mM NaCl, 10 mM sodium pyrophosphate,
50 mM sodium fluoride, 1 mM Na3VO4, 1 mM phenylmethyl-
sulfonyl fluoride, 10 mg/ml aprotinin, and 10 mg/ml leupeptin).
Protein samples were harvested as the supernatant following
centrifugation at 12,800 g for 5 minutes [40]. Alternatively,
subcellular fractions were prepared as follows. 46106 cells were
washed in PBS and lysed by incubating in digitonin lysis buffer
(75 mM NaCl, 8 mM Na2HPO4, 1 mM NaH2PO4, 1 mM
EDTA, and 350 mg/ml digitonin) for 30 seconds. After centrifu-
gation at 12,000 g for 1 minute, the supernatant (S-100 cytosolic
fraction) was collected in an equal volume of 26sample buffer.
The pellets (organelle/membrane fractions) were then washed
once in cold PBS and lysed in 16 sample buffer.
The amount of total protein was quantified using Coomassie
protein assay reagent (Pierce, Rockford, IL). 20 mg of protein were
separated on precast SDS-PAGE gels (Invitrogen, CA) and
electrotransferred onto nitrocellulose membranes. Blots were
reprobed with antibodies against b-actin (Sigma) or a-tubulin
(Oncogene, La Jolla, CA) to ensure equal loading and transfer of
proteins. Blots were probed with primary antibodies including:
anti-Mcl-1, anti–caspase-3, and anti–cytochrome c (BD Biosci-
ences, San Jose, CA); anti-Bim and anti–smac/DIABLO (Milli-
pore, Billerica, MA); anti-PARP (Biomol, Plymouth Meeting, PA);
anti-cleaved caspase-3 and anti-phospho-p44/42 (Thr202/
Tyr204) MAPK (Cell Signaling, Beverly, MA); anti-Bax (Santa
Cruz Biotechnology, Santa Cruz, CA).
Immunoprecipitation (IP)
Interactions between Mcl-1 and Bim or Bak were evaluated by
co-IP analysis. CHAPS buffer (150 mmol/L NaCl, 10 mmol/L
Overcoming Mcl-1-Mediated Resistance in Myeloma
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HEPES [N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid]
pH 7.4, protease inhibitors, and 1% CHAPS) was employed to
avoid artifactual associations [43]. Cells were lysed in CHAPS
buffer and 200 mg of protein per condition were immunoprecip-
itated with 1 mg anti-Mcl-1 (Santa Cruz Biotechnology or BD
Biosciences), anti-Bak, or anti-Bim (Santa Cruz Biotechnology),
followed by Dynabeads (Dynal, Oslo, Norway). IP samples were
then subjected to Western blot analysis using anti-Bim (Millipore),
anti-Mcl-1, or anti-Bak (Santa Cruz Biotechnology) as primary
antibodies, respectively.
To monitor Bak and Bax conformational change, anti-Bax
(6A7, Sigma) or anti-Bak (Ab-1, Millipore) antibodies, which only
recognize Bax or Bak that have undergone conformational
change, were used for IP, followed by Western blot analysis using
anti-Bax and anti-Bak as primary antibodies.
Quantitative real time-PCR (qRT-PCR)
Quantitative PCR (qPCR) analysis using TaqMan gene
expression assay (assay ID, Hs03043899_m1) and 7900HT real-
time PCR system (Applied Biosystems, Foster City, CA) were
employed to quantify human Mcl-1 mRNA [20]. Human
GAPDH (Pre-Developed TaqMan Assay Reagents Control Kit)
was used as reference for quantitation. Data was analyzed using
SDS 2.3 software.
Flow cytometry
Apoptosis was monitored by annexin V-FITC staining and flow
cytometry. Primary MM cell viability was determined by trypan
blue exclusion. MM cell death was also monitored by 7-AAD
staining (0.5 mg/mL at 37uC for 30 min). Cell death of MM cells
co-cultured with HS-5 stromal cells was determined by monitoring
the percentage of 7AAD+ cells in the GFP+ gated population (i.e.,
myeloma cells labeled with GFP) by flow cytometry.
Clonogenic assays
Colony-forming ability was evaluated using a previously
described soft agar cloning assay [30]. In brief, U266 cells, with
or without HS-5 cells, were treated with 400 nM
CEP389167.5 mM PD184352 for an additional 48 h, after which,
cells were washed free of drug and plated in soft agar for 21 days.
Colonies, consisting of groups of .50 myeloma cells, were then
scored for each condition. In this system, the morphology of
myeloma cell colonies with or without HS-5 cells was identical,
and clearly distinguishable from HS-5 colonies. In addition,
colonies were stained with 0.1% crystal violet for 3 hrs and images
captured by digital camera (Model: Power shot A640). To confirm
myeloma cell colony-forming ability of cells co-cultured with HS-5
cells, the colony-forming ability of GFP+ U266 cells was monitored
by fluorescence microscopy; colonies were defined as clusters of
.50 green fluorescent protein–positive (GFP+) cells. Within the
same field, bright field images were captured for all colonies,
including HS-5 cells.
Statistical analysis
Values represent the means 6 SD for at least 3 separate
experiments performed in triplicate. Significance of differences
between experimental variables was determined using the
Student’s t test. Median dose effect analysis [44] of apoptosis
induction by PD184352 and CEP3891 administered over a range
of concentrations at a fixed ratio was performed to assess
synergism using the software program Calcusyn (Biosoft, Fergu-
son, MO) according to the manufacturer’s instructions. CI values
less than 1.0 indicate synergism.
Results
Simultaneous inhibition of Chk1 and MEK1/2 down-
regulates Mcl-1 and effectively induces apoptosis in MM
cells
Because UCN-01 displays off-target effects towards multiple
proteins including PKC, CDKs, and PDK1 [45], a newer
generation of more specific Chk1 inhibitors (e.g., CEP3891) have
recently been developed [29]. U266 cells exposed to 400 nM
CEP3891 (48 h) experienced minimal toxicity, while combined
treatment with a sub-toxic concentration of the MEK1/2 inhibitor
PD184352 (7.5 mM) synergistically increased cell death (Fig. 1A
and Fig. S1A), with combination index values less than 1 over a
range of concentrations by Median Dose Effect Analysis (inset).
Dose response analysis yielded consistent results (Fig. S1B, C).
Similar interactions also occurred in multiple other MM cell lines,
including H929, MM1.S, MM1.R, and 8226 (Fig. S1D–F).
Exposure of U226 cells to CEP3891 down-regulated Mcl-1, an
event enhanced when combined with PD184352, accompanied by
increased Bax mitochondrial translocation, cytosolic release of
cytochrome C and Smac (Fig. 1B), and cleavage of caspase-3 and
PARP (Fig. S1G). Similarly, Mcl-1 down-regulation and
increased caspase 3 cleavage following combined treatment were
observed in several other MM lines e.g., 8266, H929, MM1.S, and
OPM2 (Fig. S2A). Interestingly, qRT-PCR revealed that while
PD184352 modestly increased mRNA levels of Mcl-1, CEP3891
alone or in combination partially but significantly reduced Mcl-1
mRNA levels at 6, 16, and 42 h in U266 cells, compared to
untreated control (Fig. 1C and Fig. S2B). However, inhibition of
protein translation by CHX or proteasomal degradation by MG-
132 had a little effect on Mcl-1 down-regulation by CEP3891 in
combination with PD184352 (Fig. 1D and Fig. S2C). On the
other hand, exposure to PD184352 markedly up-regulated Bim
(Fig. S1G), as described earlier [40]. Together, these results raise
the possibility that whereas CEP3891 down-regulates Mcl-1 and
PD187352 up-regulates Bim, the anti-MM activity of this
combination regimen may involve cooperative effects of these
two events.
Ectopic overexpression of Mcl-1 fails to protect MM cells
from the MEK/Chk1 inhibition strategy
To assess effects of simultaneous MEK/Chk1 inhibition on MM
cells overexpressing Mcl-1, U266 cells ectopically expressing Mcl-1
(U266/Mcl-1) were employed. In contrast to pronounced resis-
tance of U266/Mcl-1 cells to bortezomib (P,0.01 vs empty vector
control U266/EV), the CEP3891/PD184352 regimen induced
equivalent apoptosis in both cell lines (P.0.05, Fig. 1E).
Interestingly, as shown in Fig. 1F, CEP3891 alone or in
combination clearly down-regulated Mcl-1, while PD184352 up-
regulated Bim presumably via ERK1/2 inactivation, together
markedly increasing PARP cleavage in both empty vector control
(U266/EV) and U266/Mcl-1 cells. Similar results were obtained
in 8226 cells ectopically overexpressing Mcl-1 (Fig. S2D, E).
These findings argue that Mcl-1 over-expression, which confers
marked resistance to bortezomib, does not confer cross-resistance
to the MEK/Chk1 inhibitor regimen.
Increased binding of Bim to Mcl-1 is associated with
release of Bak from Mcl-1 following combined Chk1/
MEK1/2 inhibitor treatment
In view of evidence that in addition to the relative protein levels
of pro-and anti-apoptotic Bcl-2 family proteins, interactions
between these agents may also be involved in determination of
Overcoming Mcl-1-Mediated Resistance in Myeloma
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cell fate [46], associations between Mcl-1 and Bim or Bak were
then examined. PD184352+/2CEP3891 increased the amount of
Bim co-immunoprecipitating with Mcl-1, presumably due to Bim
up-regulation, accompanied by dissociation between Mcl-1 and
Bak (Fig. 2A, B). Similar phenomena were also observed in Mcl-
1-overexpressing cells (Fig. 2C, D). Moreover, combined
treatment induced activation of both Bak and Bax in parental
U266 cells (Fig. 2E) as well as in their counterparts ectopically
Figure 1. Combined treatment with CEP3891/PD184352 down-regulates Mcl-1 and induces apoptosis in MM cells including those
ectopically over-expressing Mcl-1. (A) U266 cells were co-exposed to 400 nM CEP389167.5 mM PD184352 for indicated interval, after which cell
death was monitored by flow cytometry. Values represent the means and SD for three separate experiments performed in triplicate (* P,0.01 or **
P,0.001). U266 cells were treated (48 h) with a range of concentrations of CEP38916PD184352 at a fixed ratio (6:1), after which median dose effect
analysis was used to characterize the nature of the interaction (inset). (B) U266 cells were treated with 400 nM CEP38916PD184352 at the indicated
concentrations for 16 h, after which subcellular fractions were prepared as discribed in meterial and method. Western blot analysis was performed
using the indicated primary antibodies. WCL, whole cell lysate; S-100, cytosol; pellet, mitochondria-enriched fraction; Cyto c = cytochrome c. For these
and all subsequent Western blot analyses, each lane was loaded with 20 mg of protein; blots were stripped and re-probed with a-tubulin (a-tub) or b-
actin (b-act) antibodies to ensure equal loading and transfer; two additional studies yielded equivalent results. (C) U266 cells were treated with
400 nM CEP389167.5 mM PD184352 for 16 and 42 h, after which real-time qRT-PCR was performed to quantify Mcl-1 mRNA. Values represent the
means and SD for three separate experiments. (D) U266 cells were incubated with 400 nM CEP389167.5 mM PD184352 in the presence or absence of
300 nM MG-132 (16 h, upper) or 1 mM CHX (3, 6, and 16 h, lower), after which protein levels of Mcl-1 were assessed by Western blot analysis. (E) U266
cells were stably transfected with a construct encoding human full-length Mcl-1 or empty vector (EV). Following treatment with 500 nM
CEP389167.5 mM PD184352 for 48 h, the percentage of dead cells was determined by flow cytometry. In parallel, empty-vector and Mcl-1 over-
expressing U266 were treated with 5 nM bortezomib as a control. Values represent the means and SD for three separate experiments performed in
triplicate. (F) Alternatively, cells were subjected to Western blot analysis using the indicated primary antibodies. CF, cleavage fragment.
doi:10.1371/journal.pone.0089064.g001
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expressing Mcl-1 (Fig. 2F). Release of Bak from Mcl-1 also led to
its activation in 8226 cells ectopically over-expressing Mcl-1 (Fig.
S2F). To test the possibility that Mcl-1 may also be disabled
through Noxa up-regulation, as reported in the case of bortezomib
[47], Western blot analysis was performed to monitor Noxa
expression in various MM cell lines. However, in contrast to
findings involving bortezomib, these studies revealed no clear
induction of Noxa following exposure to PD184352 alone or in
combination with CEP3891 (Fig. S3A). These findings support
the notion that the MEK/Chk1 inhibitor regimen up-regulates
Bim and increases binding of Bim to Mcl-1, leading to Bak release
from Mcl-1, followed by Bak and Bax activation. Collectively,
these findings provide another mechanism, in addition to Mcl-1
down-regulation, that may contribute to circumvention of Mcl-1-
dependent drug resistance.
Bortezomib-resistant MM cells displaying increased Mcl-1
expression do not display cross-resistance to the MEK/
Chk1 inhibitor regimen
Parallel studies were performed in bortezomib-resistant U266
cells (PS-R) generated by continuously culturing in progressively
increasing bortezomib concentrations. These cells displayed
pronounced resistance to bortezomib (Fig. 3A) in association
with up-regulated Mcl-1 protein (inset) and mRNA levels
compared to parental U266 cells (Fig. S3B). Notably, these cells
were fully sensitive to combined treatment with CEP3891/
PD184352 (Fig. 3B, P.0.05 vs U266 cells). Moreover, the
combination was highly synergistic (CI,0.5) in bortezomib-
resistant cells over a range of drug concentrations (inset).
Furthermore, exposure to CEP3891 alone or in combination with
PD184352 also clearly reduced Mcl-1 mRNA (16 h, Fig. 3C; 6 h,
Figure 2. The PD184352/CEP3891 regimen increases Bim/Mcl-1 binding, releases Bak from Mcl-1, and triggers Bak/Bax activation.
(A) and (B) U266 (A) and H929 (B) cells were exposed to 500 nM CEP38916PD184352 (7.5 mM for U266; 2.5 mM for H929) for 42 h; (C) and (D) U266
cells over-expressing Mcl-1 and their EV controls were treated as described for U266 in panel 2A. After treatment, cells were lysed in 1% CHAPS buffer
and immunoprecipitated (IP) using anti-Mcl-1 (C) or anti-Bak (D) antibodies, followed by Western blot (WB) analysis using anti-Bim, anti-Bak, or anti-
Mcl-1 antibodies as indicated. WCL were loaded to monitor Bim levels. (E) and (F) Alternatively, following 24 h treatment, IP was performed to
monitor conformational change of Bax and Bak using anti-Bax 6A7 or anti-Bak Ab-1 (for IP), and anti-Bax or anti-Bak (for WB) in parental U266 cells (E)
and their counterparts ectopically expressing Mcl-1 (F). For all IP assays, IPs without cell lysate (-lysate) and/or with IgG (instead of primary antibodies)
were carried out as controls; 200 mg protein per condition were employed for IP; IgG levels are shown to ensure equal loading of IP antibodies.
doi:10.1371/journal.pone.0089064.g002
Overcoming Mcl-1-Mediated Resistance in Myeloma
PLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e89064
Fig. S3C, P,0.01 vs untreated control) and protein levels
(Fig. 3D) in PS-R cells. Moreover, PS-R cells displayed sharply
reduced basal Bim levels compared to their parental counterparts.
Of note, PD184352 alone or in combination with CEP3891
restored Bim expression. In association with these actions, the
combination clearly increased PARP cleavage in both drug-naı¨ve
and bortezomib-resistant cell lines (Fig. 3D). Lastly, as observed in
U266 cells (Fig. 2A), PD1843526CEP3891 also increased Bim
binding to Mcl-1 (Fig. 3E) and released Bak from Mcl-1, leading
to Bak activation (Fig. 3F), accompanied by Bax mitochondrial
translocation, and cytosolic release of cytochrome c and Smac in
PS-R cells (Fig. S3D). Analogous results were observed in another
bortezomib-resistant cell line, OPM2/V10R [39] (Fig. S4A–D).
Together, these findings argue that the CEP3891/PD184352
regimen transcriptionally down-regulates and functionally disables
Mcl-1, and raise the possibility that these events may contribute to
the activity of this strategy in bortezomib-resistant MM cells.
Chk1/MEK1/2 inhibition prevents Mcl-1 up-regulation
and circumvents drug resistance induced by growth
factors
A link exists between growth factors and Mcl-1 expression in
microenvironment-mediated drug resistance to chemotherapeutic
agents in MM cells [15,17,48]. Consequently, the effects of the
MEK/Chk1 inhibitor regimen were examined in MM cells in the
presence of growth factors or stromal cell-conditioned medium.
Addition of IL-6 or IGF-1 to culture medium induced discernible
Mcl-1 up-regulation in MM cells (Fig. 4A and Fig. S4E) and
significantly protected cells from dexamethasone lethality
(Fig. 4B). In contrast, these growth factors conferred no
protection against combined treatment with CEP3891/
PD184352 (Fig. 4B). Moreover, CEP3891/PD184352 blocked
IL-6- and IGF-1-induced Mcl-1 up-regulation, and induced
increases in PARP cleavage in either the presence or absence of
these growth factors (Fig. 4C and Fig. S4E). Moreover,
conditioned medium derived from human BM stromal HS-5 cells
also clearly up-regulated Mcl-1 (Fig. 4D), and significantly
blocked dexamethasone-induced cell death (Fig. 4E, F) as
reported earlier [20,49]. However, conditioned medium was
unable to diminish CEP3891/PD184352 lethality in H929
(Fig. 4F), U266 (Fig. S4F), or 8226 cells (Fig. S5C, P.0.05 in
each case).
Stromal cells fail to prevent Mcl-1 down-regulation and
MM cell death induced by MEK/Chk1 inhibition
To assess effects of interactions with stromal cells on MM cell
responses to the MEK/Chk1 inhibitor regimen, MM cells stably
expressing luciferase in co-culture with HS-5 cells were used to
monitor MM cell viability. Co-culture with HS-5 cells significantly
rescued U266 cells (luc+) from lethality of dexamethasone or
melphalan (Fig. 5A), as reported earlier [42]. In sharp contrast,
MM cells co-cultured with HS-5 did were, if anything (P,0.05),
more sensitive to combined treatment with CEP3891/PD184352
(Fig. 5B), reflected by diminished bioluminescent signals propor-
tional to the reduced number of viable cells [11]. Moreover,
following CEP3891/PD184352 exposure, fluorescence microsco-
py revealed a marked increase in 7-AAD uptake (red) by GFP-
expressing U266 cells (green) in the presence of HS-5 cells
(Fig. 5C). This finding was further validated quantitatively by flow
cytometry (Fig. S4F). Similar data were obtained in luciferase-
expressing H929 cells (Fig. S5A, B) or GFP-labeled 8226 cells
(Fig. S5C, D). Importantly, analogous phenomena were also
observed in luciferase-expressing bortezomib-resistant PS-R cells
(Fig. S5E). Finally, co-treatment with CEP3891/PD184352
markedly suppressed colony formation of U266 cells in either
the presence or absence of HS-5 cells (Fig. 5D and Fig. S6A–C).
Expression of Mcl-1 and Bim were then examined in MM cells
treated with CEP3891/PD184352 in the presence of HS-5-
conditioned medium or HS-5 cells. Notably, CEP3891/PD184352
largely blocked Mcl-1 up-regulation induced by both HS-5 cells
and conditioned medium, while up-regulating Bim expression,
accompanied by increased caspase-3 cleavage (Fig. 5E and S6D).
Collectively, these findings suggest that MM bone marrow
microenvironmental factors are ineffective in protecting MM cells
from the MEK/Chk1 inhibitor regimen.
MEK/Chk1 inhibition down-regulates Mcl-1 and induces
cell death in primary MM samples
Lastly, the effects of this regimen were tested in primary MM
samples. Co-exposure to CEP3891 and PD184352 resulted in
significant increases in cell death in CD138+ MM cells isolated
from 8 of 9 primary samples analyzed (Fig. 6A), but exerted
minimal toxicity toward their CD1382 counterparts (Fig. 6B).
Notably, in one sample (#13) in which a sufficient number of
CD138+ cells were available for Western blot analysis, combined
treatment induced marked Mcl-1 down-regulation, associated with
caspase-3 and PARP cleavage in CD138+ cells (Fig. 6C).
Interestingly, CD1382 cells exhibited minimal basal Mcl-1 level
and little evidence of PARP or caspase-3 cleavage after drug
treatment. Mcl-1 down-regulation following combined treatment
was validated in two additional CD138+ samples (Fig. 6C lower
and Fig. S6E). Moreover, the lack of toxicity of the regimen to
non-neoplastic cells was also observed in normal human CD34+
cells (Fig. S6F). These findings raise the possibility that the MEK/
Chk1 inhibitor regimen may act selectively against MM cells.
Discussion
Mcl-1 has been implicated in the development of diverse
malignancies, including those of hematopoietic origin such as
MM, mantle cell lymphoma, and acute myelogenous leukemia
[3,50,51]. In particular, it plays an important role in the survival of
MM cells [4,5,10], as well as in the development of resistance to
proteasome inhibitors such as bortezomib [7–9], a class of agents
that are highly active as first-line treatment for patients with MM.
Moreover, Mcl-1 up-regulation has been linked to microenviron-
mental stromal cell-related drug resistance in MM [17,48].
Targeting Mcl-1, a short half-life protein [6], induces rapid
apoptosis in MM cells, even with continuous expression of other
anti-apoptotic proteins [3,4]. Therefore, the central regulatory role
of Mcl-1 as a survival and proliferation checkpoint factor makes
this protein an attractive target for therapeutic intervention in MM
[3,5]. Because Mcl-1 abundance is reciprocally regulated by gene
expression at multiple levels (e.g., transcriptional, translational) as
well as proteasomal degradation [5,6], various strategies have been
employed to suppress its expression, including the use of
transcriptional, translational, and deubiquitinase inhibitors
[21,23,52]. In addition, phosphorylation influences interactions
between Mcl-1 and pro-apoptotic proteins (e.g., Bim and Bak),
thereby modifying its anti-apoptotic functions [53,54]. The present
results demonstrate for the first time that a strategy combining
Chk1 with MEK1/2 inhibitors effectively kills MM cells, including
those exhibiting Mcl-1 up-regulation and acquired resistance to
bortezomib, as well as MM cells cultured in the presence of
microenvironmental factors known to confer resistance to standard
chemotherapeutic agents. They also raise the possibility that this
combination regimen may act synergistically due to cooperative
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effects including down-regulation of Mcl-1 (by the Chk1 inhibitor
CEP3891) and disabling of Mcl-1 anti-apoptotic functions (e.g.,
sequestration of Bak) in association with Bim up-regulation and
increased Bim/Mcl-1 binding (by the MEK1/2 inhibitor
PD184352). However, while the contribution of these events to
the activity of this regimen in Mcl-1-overexpressing, bortezomib-
resistant cells appears plausible, an alternative explanation e.g.,
that this regimen acts by triggering one or more Mcl-1-
independent cell death pathways cannot presently be excluded.
Efforts to investigate this possibility are currently underway.
The mechanism by which CEP3891 reduced expression of Mcl-
1 remains to be fully elucidated, but appears to involve, at least in
part, inhibition of gene transcription. On the other hand,
interruption of the MEK1/2/ERK1/2 pathway by PD184352 is
known to up-regulate Bim through a post-translational mechanism
[40,55]. Together, these actions may act in concert to attenuate
Mcl-1 anti-apoptotic functions. The balance between Mcl-1 and
Bim levels has been identified as a critical determinant of MM cell
fate [56]. In this context, Bim up-regulation by MEK1/2
inhibition increased the amount of protein available for binding
to Mcl-1, an event reported to disrupt Mcl-1 function [34].
Indeed, the current strategy increased the amount of Bim bound to
Mcl-1, accompanied by release of Bak from Mcl-1 and activation
of Bak and Bax. Consistent with these results, recent studies
indicate that alterations in the associations/interactions between
pro- and anti-apoptotic proteins may play a role in determining
cell fate [32,46]. Thus, the finding that combined treatment with
CEP3891 and PD184352 was active against cells ectopically
Figure 3. Bortezomib-resistant MM cells exhibiting Mcl-1 up-regulation and Bim down-regulation does not display cross-resistance
to PD184352/CEP3891. (A) Parental U266 cells and their bortezomib-resistant counterparts (PS-R) were exposed to 20 nM bortezomib (btzmb) for
24 h, after which the percentage of apoptotic cells were determined by Annexin V staining and flow cytometry. Western blot analysis was performed
to monitor Mcl-1 protein (inset). (B) U266 and PS-R cells were treated with 500 nM CEP389167.5 mM PD184352 for 48 h, after which the extent of
apoptosis (Annexin V+ cells) was determined by flow cytometry. PS-R cells were exposed to a range of concentrations of CEP38916PD184352 at a
fixed ratio (1:15) for 48 h, after which median dose effect analysis was used to characterize the nature of the interactions using cell death (7AAD+) as
an endpoint (inset). (C) and (D) Alternatively, following treatment with 500 nM CEP389167.5 mM PD184352, real-time qRT-PCR and Western blot
analysis were performed to monitor Mcl-1 mRNA levels (16 h, C) and expression of the indicated proteins (40 h, D). (E) and (F) In parallel, following
42 h-exposure to 500 nM CEP389167.5 mM PD184352, PS-R cells were subjected to immunoprecipitation (IP) followed by Western blotting to assess
interactions between Mcl-1/Bim (E) and Mcl-1/Bak (F, upper), or Bak conformational change (F, lower). WCL was loaded to monitor protein levels. For
analyses of flow cytometry and real-time qRT-PCR, values represent the means and SD for three separate experiments.
doi:10.1371/journal.pone.0089064.g003
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expressing Mcl-1, which confers striking bortezomib resistance,
suggests that the MEK/Chk1 inhibitor strategy may effectively
circumvent Mcl-1-dependent drug resistance.
Interpretation of the impact of Bim/Mcl-1 binding has differed
in the literature, possibly reflecting cell type- and stimulus-
dependent phenomena. For example, in Jurkat leukemia cells,
disruption of Bim/Mcl-1 binding has been postulated to contrib-
ute to granzyme B-mediated apoptosis [57]. Moreover, bortezo-
mib has been reported to induce apoptosis in myeloma cells by
dissociation of Bim/Mcl-1 complexes, most likely through Noxa
induction [47]. In contrast, an increase in the Bim/Mcl-1
association has been associated with enhanced apoptosis in
leukemia cells co-exposed to BH3 mimetics and MEK1/2
inhibitors [35]. Moreover, rescue of fibroblasts from serum
deprivation-induced cell death by growth factors has been
attributed to Bim/Mcl-1 dissociation due to ERK1/2 activation
[33]. In this context, the interaction between Bim and pro-survival
Bcl-2 family proteins (e.g., Mcl-1) is regulated by ERK1/2-
dependent phosphorylation of Bim [34]. This phenomenon has
been attributed to promotion of Bim degradation following its
release from Mcl-1, as well as preservation of Mcl-1 anti-apoptotic
actions [33,34]. The present findings are compatible with the latter
mechanism in that an increased binding between Mcl-1 and Bim
was associated with release of Bak from Mcl-1, even in cells over-
expressing Mcl-1. Together, these results suggest that as in the case
of MEK1/2 inhibition [33,34], increased Bim/Mcl-1 association is
likely to play a pro-apoptotic role in the ability of this regimen to
circumvent Mcl-1-dependent drug resistance in MM cells.
The bone marrow microenvironment, composed of BMSCs,
stromal factors (including cytokines and growth factors), and
Figure 4. PD184352/CEP3891 attenuates Mcl-1 up-regulation and drug-resistance induced by growth factors. (A) U266 cells were
cultured in serum-free medium for 6 h, followed by addition of IL-6 (100 ng/ml) or IGF-1 (400 ng/ml) for 2 h and 18 h, after which cells were lysed
and subjected to Western blot analysis to assess expression of Mcl-1. (B) U266 cells were treated with 400 nM CEP3891+7.5 mM PD184352 or 50 mM
dexamathasone (Dex) for 40 h in either the presence or absence of IL-6 or IGF-1. After treatment, the percentage of dead cells was evaluated by flow
cytometry (** P,0.01 vs. without IL-6 or IGF-1). (C) After pre-incubation with either IL-6 or IGF-1 for 1 h, U266 cells were exposed to 400 nM
CEP3891+5 mM PD184352 for 4 h, after which Western blot analysis was performed to monitor Mcl-1 expression and PARP cleavage. (D) MM.1S,
H929, RPMI8226, and U266 cells were serum-starved for 6 h, and then cultured for an additional 24 h in either fresh 10% FBS medium as a control or
conditioned medium (CM) derived from HS-5 cell cultures, after which Western blot analysis cells was performed to assess Mcl-1 expression. (E) U266
cells stably expressing GFP were pre-cultured with HS-5 cells or in the presence of HS-5 CM for 48 h, followed by treatment with 50 mM
dexamathasone for an additional 40 h. After treatment, the percentage of dead (7AAD+) cells in the GFP+ population was determined by flow
cytometry. (F) H929 cells were exposed to 6 mM dexamathasone or 400 nM CEP3891+2.5 mM PD184352 for 38 h in the presence of HS-5 CM, after
which the percentage of apoptotic (Annexin V+) cells was determined by flow cytometry. For panels 4E and F, Ctrl = 10% FBS medium. For flow
cytometry, values represent the means 6 SD for three separate experiments.
doi:10.1371/journal.pone.0089064.g004
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extracellular matrix proteins, is essential for the survival and
growth of MM cells as well as resistance to diverse therapies
[11,15]. Although the precise role of Mcl-1 in stromal cell-
mediated drug resistance has not yet been clearly defined, it is
known that MM cells adhere to and induce bone marrow stromal
cells (BMSCs) to secret multiple stromal factors (e.g., IL-6), which
in turn promote MM cell survival [3,5]. Mcl-1 is required for both
VEGF and IL-6-promoted MM survival and proliferation [16–
Figure 5. BMSCs fail to protect MM cells from PD184352/CEP3891 lethality. (A) and (B) U226 cells stably expressing luciferase were co-
cultured for 24 h with HS-5 cells (pre-cultured for 48 h), and then treated with either 50 mM dexamethasone (Dex) or 30 mM melphalan (Mel, A) or
400 nM CEP389167.5 mM PD184352 (B) for an additional 48 h. Bioluminescence intensity, which is proportional to the number of living cells, was
monitored to assess cell viability. Values represent the means and SD for three separate experiments performed in triplicate. UT = untreated;
RLU= relative light unit. (C) GFP-expressing U266 cells were co-cultured for 48 h with HS-5 cells (pre-cultured for 48 h) on the 4-well chamber slides,
after which cells were treated with 400 nM CEP389167.5 mM PD184352 for an additional 40 h. Cells were then stained with 7AAD and images
captured by an inverted fluorescence microscope (Olympus 1X71, 206objective) with the filters suitable for 7AAD (red) or GFP (green). In parallel,
bright field (BF) images were also captured for the same areas. (D) After treatment as described in panel 5B, GFP-expressing U266 cells were washed
free of drugs and then plated with HS-5 cells on soft agar. After incubation for 21 days, the colony-forming ability of GFP+ U266 cells was assessed
under fluorescence microscopy (Olympus 1X71, 46objective); colonies were defined as clusters of .50 GFP+ cells. Bright field images were captured
for comparison. The microscopic images are representative of three separate experiments. (E) H929 cells were treated with 300 nM CEP389162.5 mM
PD184352 for 48 h under the conditions as follows: a) 10% FBS medium as control (lanes 1–4); b) HS-5-derived conditional medium (CM, lanes 5–8);
and c) co-culture with HS-5 (lanes 9–12). In parallel, HS-5 cells alone (lanes 13–16) were treated for comparison. After drug treatment, Western blot
analysis was conducted to monitor the expression of Mcl-1 and Bim, as well as caspase 3 cleavage.
doi:10.1371/journal.pone.0089064.g005
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18]. Moreover, stromal factors (e.g., IL-6) have also been
implicated in resistance of MM cells to both conventional
cytotoxic drugs and novel targeted agents [11,49,58]. Further-
more, drug resistance conferred by various stromal factors (e.g.,
IL-6) has been related, at least in part, to Mcl-1 up-regulation in
MM cells [18,59]. Another major mechanism underlying the
cytoprotective actions of stromal factors involves activation of the
MEK1/2/ERK1/2 pathway, which leads to Bim phosphorylation
and proteasomal degradation [16,58,60]. Consequently, MEK1/2
inhibitors have been reported to overcome bone marrow stromal
factor-mediated drug resistance in MM cells [60,61]. In this
context, the MEK/Chk1 inhibitor strategy, which both down-
regulates Mcl-1 and up-regulates Bim, may act in a cooperative
manner to overcome BMSC- and stromal factor-mediated drug
resistance. Indeed, this regimen was fully active against MM cells
cultured in the presence of stromal factors (e.g., IL-6 and IGF-1),
Figure 6. The PD184352/CEP3891 regimen down-regulates Mcl-1 and induces cell death in primary CD138+ MM cells. (A) and (B)
Primary CD138+ MM cells (A) and their normal CD1382 counterparts (B) were isolated from bone marrow samples obtained from nine patients with
MM, and exposed to 500 nM CEP389165 mM PD184352 for 24 h. After treatment, cell death was examined by trypan blue exclusion. (C) Alternatively,
Western blot analysis was performed to monitor expression of Mcl-1 as well as cleavage of PARP and caspase 3 in the CD138+ and/or CD1382
populations. Each lane was loaded with 10 mg of protein. (D) A mechanistic model of circumvention of Mcl-1-dependent drug resistance by the Chk1/
MEK inhibitor regimen. Mcl-1 plays an important role in both the survival of MM cell and sensitivity to various anti-MM agents, including bortezomib,
as well as contributing to microenvironmental forms of drug resistance. A regimen combining a MEK1/2 inhibitor (MEKi) and a Chk1 inhibitor (Chk1i)
acts at multiple levels in MM cells displaying Mcl-1-dependent bortezomib resistance, including a) down-regulation of Mcl-1 through a transcriptional
mechanism; b) up-regulation of Bim and increased Bim/Mcl-1 binding, accompanied by release and activation of Bak and Bax; c) induction of MOMP
(mitochondrial outer membrane permeabilization) and apoptosis; and d) possibly alternative Mcl-1-independent mechanism(s) of action (MOAs).
doi:10.1371/journal.pone.0089064.g006
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stromal cell-derived conditioned medium, or BMSCs. Notably, the
regimen retained its ability to down-regulate Mcl-1 and up-
regulate Bim in the presence of these microenvironmental factors
that confer resistance to conventional anti-MM agents.
Multiple mechanisms of resistance to proteasome inhibitors
such as bortezomib have been described, including mutation or
amplification of proteasome sub-units, up-regulation of anti-
oxidant proteins, and overexpression of anti-apoptotic proteins,
etc. [2,62,63]. Among these mechanisms, up-regulation of Mcl-1
has often been implicated in proteasome inhibitor resistance [7,9].
For example, administration of proteasome inhibitors (e.g.,
bortezomib) induce Mcl-1 accumulation by blocking its proteaso-
mal degradation [64], thus limiting their anti-MM activity [7,8].
Consistent with these findings, MM cells ectopically expressing
Mcl-1 were highly resistant to bortezomib, while bortezomib-
resistant MM cells (e.g., PS-R cells), which acquired resistance
through continuous culture in progressively higher bortezomib
concentrations, exhibited both Mcl-1 up-regulation and Bim
down-regulation [20]. Significantly, neither of these cells displayed
cross-resistance to MEK/Chk1 inhibition. Importantly, the
MEK/Chk1inhibitor strategy was able to release Bak from Mcl-
1 in both drug-naı¨ve and bortezomib-resistant MM cells. Under
normal conditions, Bak is held in check by its inhibitory
associations with both Mcl-1 and Bcl-xL [65], while interventions
that down-regulate Mcl-1 untether Bak, leading to Bak activation
and apoptosis [24,34]. Of note, Chk1/MEK1/2 inhibition also
untethered Bak from Mcl-1, and triggered Bak activation in
bortezomib-resistant MM cells either endogenously displaying
high levels of or ectopically expressing Mcl-1.
It is noteworthy that the MEK/Chk1 inhibitor regimen also
down-regulated Mcl-1 in primary CD138+ MM cells. Interesting-
ly, basal Mcl-1 levels were not detectable in non-malignant bone
marrow CD1382 cells. It is therefore tempting to speculate that
higher basal expression of Mcl-1 in MM cells reflects the
dependence of neoplastic cells on this protein for survival. This
notion is supported by evidence that high Mcl-1 expression
discriminates between primary MM versus normal cells, and also
correlates with disease progression and clinical outcome [10]. If
validated, this mechanism could potentially account for the
preferential lethality of the regimen towards MM cells. However,
additional studies will be required to establish the basis for this
selectivity more definitively. Such studies are currently underway.
In summary, the present findings demonstrate that a strategy
combining Chk1 with MEK1/2 inhibitors is shows pronounced
activity against MM cells with acquired bortezomib-resistance or
ectopically expressing high levels of Mcl-1, an anti-apoptotic
protein which has been implicated in resistance to numerous anti-
MM agents including bortezomib [8,9] as well as in drug
resistance conferred by microenvironmental factors [15,48]. A
hypothetical model outlining these mechanisms is summarized in
(Fig. 6D). According to this model, up-regulation of Mcl-1
contributes to acquired bortezomib-resistance and the pro-survival
effects of microenvironmental factors. The MEK/Chk1 inhibitor
combination strategy acts through Mcl-1 down-regulation (e.g., by
CEP3891), as well as Bim up-regulation (e.g., by PD184352),
which increases the binding of Bim to Mcl-1 and unleashes Bak
from Mcl-1. These events act cooperatively to trigger mitochon-
drial membrane permeabilization, leading to caspase activation
and apoptosis. Finally, an additional possibility exists that the
Chk1/MEK1/2 inhibitor regimen may trigger Mcl-1-independent
cell death pathways. Collectively, these findings provide evidence
arguing for an important role for Mcl-1 in multiple forms of drug
resistance (e.g., acquired bortezomib- and microenvironmental
factor-mediated drug resistance) in MM cells. They also raise the
possibility that a strategy combining Chk1 with MEK1/2
inhibitors may be effective against various forms of Mcl-1-related
drug-resistance. Accordingly, efforts to pursue this strategy further
in humans are in development.
Supporting Information
Figure S1 The PD184352/CEP3891 regimen up-regu-
lates Bim and induces apoptosis in a dose-dependent
manner in various multiple myeloma cells.
(TIF)
Figure S2 CEP3891/PD184352 transcriptionally down-
regulates Mcl-1, while ectopic over-expression of Mcl-1
fails to prevent cell death.
(TIF)
Figure S3 PD184352/CEP3891 down-regulates Mcl-1 in
bortezomib-resistant myeloma cells.
(TIF)
Figure S4 The PD184352/CEP3891 regimen is active
against bortezomib-resistant OPM-2 cells.
(TIF)
Figure S5 The PD184352/CEP3891 regimen overcomes
BMSC-mediated drug-resistance.
(TIF)
Figure S6 The PD184352/CEP3891 regimen diminishes
the colony-forming ability of myeloma cells in the
presence or absence of stromal cells.
(TIF)
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